헤모크로마토시스 : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

헤모크로마토시스는 생체 내에 철이 과잉 축적되어 생기는 철 장애입니다. 증상은 관절통, 복통, 피로, 허약, 당뇨병, 간장애, 심부전 등입니다. 위험요인으로서 가족력, 알코올 중독, 철이나 비타민 C를 포함한 영양보조식품 섭취, 당뇨병·심장병·간장 병력 등이 있습니다.

헤모크로마토시스(Hemochromatosis) 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 프로파일, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등을 정리하여 전해드립니다.

서론

• 조사 범위

헤모크로마토시스 개요

치료제 개발

• 파이프라인 제품 개요
• 기업별 파이프라인
• 대학/연구기관에서 개발된 파이프라인
• 기업에서 개발중인 제품
• 대학/연구기관에서 개발중인 제품

치료제 평가

• 표적별
• 작용기전별
• 투여 경로별
• 분자 종류별

치료제 개발 참여 기업

• Ionis Pharmaceuticals Inc
• Protagonist Therapeutics Inc
• Silence Therapeutics Plc

약제 프로파일

휴지 상태인 프로젝트

제품 개발 마일스톤

• 주요 뉴스와 프레스 릴리스

부록

도표

List of Tables

• Number of Products under Development for Hemochromatosis, H2 2019
• Number of Products under Development by Companies, H2 2019
• Products under Development by Companies, H2 2019
• Number of Products by Stage and Target, H2 2019
• Number of Products by Stage and Mechanism of Action, H2 2019
• Number of Products by Stage and Route of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019
• Hemochromatosis - Pipeline by Bond Biosciences, H2 2019
• Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
• Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H2 2019
• Hemochromatosis - Pipeline by Panorama Research Inc, H2 2019
• Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H2 2019
• Hemochromatosis - Pipeline by Silence Therapeutics Plc, H2 2019
• Hemochromatosis - Pipeline by Vifor Pharma AG, H2 2019
• Hemochromatosis - Dormant Projects, H2 2019

List of Figures

• Number of Products under Development for Hemochromatosis, H2 2019
• Number of Products under Development by Companies, H2 2019
• Number of Products by Targets, H2 2019
• Number of Products by Stage and Targets, H2 2019
• Number of Products by Mechanism of Actions, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Routes of Administration, H2 2019
• Number of Products by Stage and Routes of Administration, H2 2019
• Number of Products by Molecule Types, H2 2019
• Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H2 2019, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.

Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively.

Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)

Reasons to buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Hemochromatosis - Overview
• Hemochromatosis - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies
• Hemochromatosis - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Hemochromatosis - Companies Involved in Therapeutics Development
• Bond Biosciences
• Ionis Pharmaceuticals Inc
• La Jolla Pharmaceutical Company
• Panorama Research Inc
• Protagonist Therapeutics Inc
• Silence Therapeutics Plc
• Vifor Pharma AG
• Hemochromatosis - Drug Profiles
• Hemochromatosis - Dormant Projects
• Hemochromatosis - Discontinued Products
• Hemochromatosis - Product Development Milestones
• Appendix